Kolltan Pharmaceuticals

Antibody Oncology Therapeutics

Kolltan Pharmaceuticals, Inc. develops new generation monoclonal antibody oncology therapeutics. Its products are developed based in receptor tyrosine kinase. The company was founded in 2007 and is based in New Haven, Connecticut.

Founded in 2007
Total money raised: $80M

06511 300 George Street
Suite 530

New Haven
New Haven

Phone: 203-773-3000

Updated on Dec 20, 2013
Kolltan Pharmaceuticals at CrunchBase
Gerald McMahon President and CEO
Joseph Schlessinger Founder, Director and Chairman of Scientific Advisory Board
Jane Pritchett Henderson Senior Vice President & Chief Business Officer
Yaron Hadari Vice President, Research
Carolyn F. Sidor Senior Vice President, Clinical and Regulatory Affairs & Chief Medical Officer
Arthur Altschul Jr. Co-Founder, Chairman of the Board
Thomas Neff Board of Directors
Theresa M. LaVallee Vice President, Translational Medicine
Paul Medeiros Board of Directors
Axel Bolt Board of Directors
Stanley Choy Vice President, Finance and Administration
Peter Hirth Board of Directors
Jon Soderstrom Board of Directors
Michael Schmertzler CEO and Director
Stanley Choy Finance Executive and Business Leader

March, 2012

Kolltan Pharmaceuticals raised $25M in a Series C round

Kolltan Pharma raises $25M in equity offering

January, 2010

Kolltan Pharmaceuticals raised $10M in a Series B round

Kolltan Pharmaceuticals Closes $10M Series B Financing

October, 2009

Kolltan Pharmaceuticals raised $5M in a Series A round from Purdue Pharma and HBM BioVentures

Kolltan Pharmaceuticals, Inc.: Series A $5M

July, 2008

Kolltan Pharmaceuticals raised $40M in a Series A round from Osage University Partners, Celtic Therapeutics Holdings, HBM BioVentures, Purdue Pharma, and Tichenor Ventures


Kolltan Pharmaceuticals was founded in 2007